Koers Guizhou Xinbang Pharmaceutical Co., Ltd.
Aandelen
002390
CNE100000NG5
Farmaceutische producten
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,85 CNY | +1,05% | +4,34% | -13,29% |
Omzet 2022 | 6,35 mld. 876 mln. 820 mln. | Omzet 2023 | 6,46 mld. 892 mln. 834 mln. | Marktkapitalisatie | 8,56 mld. 1,18 mld. 1,1 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 224 mln. 30,91 mln. 28,91 mln. | Nettowinst (verlies) 2023 | 287 mln. 39,61 mln. 37,04 mln. | EV/omzet 2022 | 1,52 x |
Nettoschuld 2022 | 493 mln. 68,1 mln. 63,69 mln. | Nettoschuld 2023 | 29,4 mln. 4,06 mln. 3,79 mln. | EV/omzet 2023 | 1,33 x |
K/w-verhouding 2022 |
39,2
x | K/w-verhouding 2023 |
29,6
x | Werknemers | 5.149 |
Dividendrendement 2022 |
1,28% | Dividendrendement 2023 |
1,35% | Vrij verhandelbaar | 51,48% |
1 dag | +1,05% | ||
1 week | +4,34% | ||
Lopende maand | +1,05% | ||
1 maand | +1,32% | ||
3 maanden | -4,70% | ||
6 maanden | -15,57% | ||
Lopend jaar | -13,29% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ling Zhong Kong
CEO | Chief Executive Officer | 56 | 01-01-00 |
Ya Yun Xiao
DFI | Director of Finance/CFO | 51 | 12-05-15 |
Chuan Chen
IRC | Investor Relations Contact | 55 | 25-03-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jin Hu
BRD | Director/Board Member | 48 | 11-02-17 |
Ling Zhong Kong
CEO | Chief Executive Officer | 56 | 01-01-00 |
Jie Qing Zhang
PRN | Corporate Officer/Principal | 49 | 17-02-12 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 3,85 | +1,05% | 18 957 610 |
25-04-24 | 3,81 | +1,06% | 14 294 750 |
24-04-24 | 3,77 | -0,26% | 11 918 450 |
23-04-24 | 3,78 | +1,07% | 15 429 910 |
22-04-24 | 3,74 | +1,36% | 17 028 710 |
slotkoers Shenzhen S.E., 26 april 2024
Meer koersenWinst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-13,29% | 1 mld. | |
-15,13% | 4,49 mld. | |
-9,75% | 3,06 mld. | |
+2,14% | 3,04 mld. | |
-6,82% | 2,61 mld. | |
+47,87% | 1,81 mld. | |
+0,09% | 1,66 mld. | |
-7,89% | 1,63 mld. | |
-12,97% | 1,55 mld. | |
+33,40% | 1,41 mld. |